{"id":"W4406279616","doi":"10.1093/rheumatology/keaf009","title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","year":2025,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Astellas Pharma; Argenx; Eisai; BeiGene; Celgene; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Adverse effect; Incidence (geometry); Disease; Bristol-Myers; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01012321,0.001253144,0.002177526,0.0005364144,0.0008164852,0.001691258,0.0009428104,0.002054697,0.00221314],"category_scores_gemma":[0.004026588,0.0005057742,0.003492016,0.0004903633,0.0007356299,0.001290857,0.000707752,0.003487202,0.000719711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001093711,"about_ca_system_score_gemma":0.001742364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008281289,"about_ca_topic_score_gemma":0.001411575,"domain_scores_codex":[0.9975663,0.0009327039,0.0002514443,0.0002856101,0.0005164417,0.0004474727],"domain_scores_gemma":[0.9948508,0.0009178048,0.001830998,0.0005475667,0.0007694758,0.001083372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5214087,0.08035649,0.06929769,0.002643995,0.01185614,0.000868518,0.001240382,0.003382034,0.06067479,0.0002747186,0.01076267,0.2372339],"study_design_scores_gemma":[0.1919502,0.5761498,0.2019827,0.0003542723,0.004687368,0.001645267,0.0002470882,0.001610107,0.01135407,0.0004062247,0.00944749,0.0001653335],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803695,0.01132127,0.001379013,0.0006751697,0.0001443298,0.001652815,0.002473326,0.0001236163,0.001860947],"genre_scores_gemma":[0.983111,0.004241855,0.001436801,0.001835731,0.0002747616,0.001619221,0.005715508,0.00004703075,0.001718145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01012321,"threshold_uncertainty_score":0.05353731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.020465319317492,"score_gpt":0.3291601782873108,"score_spread":0.3086948589698188,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}